CANCERPLEX® is a large-gene panel consisting of >400 cancer-associated genes for the detection of genetic abnormalities underlying cancer with 95->99% sensitivity and specificity at low allelic fractions, determinations of Microsatellite Instability (MSI-H) and Tumor Mutation Burden (TMB-H) status to identify patients who are most likely to respond to immune checkpoint inhibition, and for the presence of HPV/EBV viral integration which may impact treatment decisions. All data generated from sequencing at the local laboratory are processed through our high-quality, high-performance analytics platform, which combines state-of-the-art, industry-leading bioinformatics tools for variant detection with GENEKEEPER® , our proprietary software and knowledgebase for variant interpretation. To date, we have profiled thousands of patients with CANCERPLEX and are proud to have reported clinically actionable variants in 93% of these patients1.




FDA-Approved & Investigational Drug Targets


Microsatellite Instability & Tumor Mutation Burden


Therapeutic Targetable Pathways


Drug Resistance Genes





Single Nucleotide Variants



Insertions and Deletions



Copy Number Variation gain (>2.5 fold change)



Copy Number Variation loss (<0.75 fold change)



Structural Variants



Microsatellite Instability



Viral Integration



*10% MAF detection limitation


The report contains a list of potential therapies targeting the genomic changes unique to the patient, including

FDA-approved therapies in patient’s cancer type


Clinical trials enrolling patients with the cancer type


FDA-approved therapies in other cancer types


High success rate

Quality results obtained from as little as 50ng DNA in >94% tissue samples

Fast turnaround time

Only 7-10 business days

Comprehensive molecular profile

  • All types of possible genomic changes (e.g., SNVs, indels, CNVs and fusions)
  • The patient’s likelihood to respond to immunotherapy (i.e., tumor mutational burden and MSI)
  • Cancer-related viruses

Variety of tissue types

◊ Solid tumors   ◊ Pleural effusions   ◊ Fine needle aspirates

Unparalleled clinical actionability

93% of patients matched with targeted  therapies

Dedicated real-time support

  • KEW updates its gene panels and GENEKEEPER database to stay current and actionable
  • KEW provides one-on-one support to oncologists to help make the process go smoothly and to answer any questions they may have about the test results

Learn more about how comprehensive genomic profiling can benefit you.

Molecular Laboratory

Expand your current internal precision medicine program.

Learn More


Send samples directly to KEW for sequencing and clinical report.

Learn More

Patients & Caregivers

See how comprehensive genomic profiling can benefit you.

Learn More

  1. Eifert C, Pantazi A , Sun R, Xu J, Cingolani P, Heyer J, Russell M, Lvova M, Ring J, Tse J, Lyle S, Protopopov A.   Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. PERSONALIZED MEDICINE. Vol.14,NO.4

Call us




303 Wyman Street, Office #349
Waltham, MA 02451